Human papillomavirus (HPV) is widely known to cause nearly all cases of cervical cancer. However, you might not know that HPV also causes 70 percent of oropharyngeal cancer, a subset of head and neck cancers that affect the mouth, tongue, and tonsils. Although vaccines that protect against HPV infection are now available, they are not yet widespread, especially in men, nor do they address the large number of currently infected cancer patients.
You are here
A new blood test developed by University of North Carolina Lineberger Comprehensive Cancer Center researchers shows promise for tracking HPV-linked head and neck cancer patients to ensure they remain cancer-free after treatment.
A highly sensitive blood test that detects minute traces of cancer-specific DNA has been shown to accurately determine whether patients with HPV-related oropharyngeal squamous cell carcinoma (OPSCC) are free from cancer following radiation therapy. Findings will be presented today at the 60th Annual Meeting of the American Society for Radiation Oncology (ASTRO).
Humanpapilloma virus (HPV) is now the leading cause of certain types of throat cancer. Dr. Michael Moore, director of head and neck surgery at UC Davis and an HPV-related cancer expert, answers some tough questions about the trend and what can be done about it.
Q: What is HPV and how is it related to head and neck cancers?
The Case Western Reserve-led research team will analyze computerized images of tissue samples for patterns which could become "biomarkers," or predictors, for determining relative risk for recurrence in one particularly common type of head and neck cancers.
Those tumors, known as oropharyngeal cancers, occur primarily at the base of the tongue and in the tonsils.
Human papilloma virus (HPV), the culprit behind cervical cancer and some forms of head and neck cancer may hide in small pockets on the surface of tonsils in people not known to carry the virus. The finding, reported by University of Rochester Medical Center researchers in the Journal of the American Medical Association, could be pivotal for the prevention of oropharyngeal cancers that form on the tonsils and tongue.
Certain head and neck cancers that are positive for high-risk types of human papillomavirus (HPV) have a better prognosis and may need less aggressive treatment.
To help ensure that patients with these cancers are accurately diagnosed and effectively treated, the College of American Pathologists (CAP) today released its newest evidence-based practice guideline, "Human Papillomavirus (HPV) Testing in Head and Neck Carcinomas,"
Tobacco and alcohol use may be the most common cause of head and neck cancers, but a new culprit has come on the scene in recent years.
The human papillomavirus (HPV) is now responsible for more than 60 percent of cases of oropharyngeal cancer diagnosed at Penn State Milton S. Hershey Medical Center, according to Dr. David Goldenberg, professor of surgery and medicine and director of Head and Neck Surgery.
Oropharyngeal cancer can affect the back third of the tongue, the soft palate, side and back walls of the throat and the tonsils.
A blood test for the human papillomavirus, or HPV, may help researchers forecast whether patients with throat cancer linked to the sexually transmitted virus will respond to treatment, according to preliminary findings from the University of North Carolina Lineberger Comprehensive Cancer Center.
The proportion of oral squamous cell carcinoma (OSCC) patients infected with the human papillomavirus (HPV) could be around a third, with high-risk versions of the virus accounting for almost three-quarters of those affected, indicate Taiwanese study results.
The findings also show that patients with the high-risk HPV variant HPV-18 were significantly more likely to develop secondary malignancies than their counterparts without this variant.